基于治疗药物监测调整依库珠单抗给药间隔的前瞻性多中心研究
依库珠单抗维持期统一为1200 mg每2周,但目标谷浓度50-100 mg/L下许多患者存在过度暴露。本研究分两阶段:先用40例患者建立群体药代动力学模型,预测36例(90%)可延长间隔1周;第二阶段对15例预测谷浓度>100 mg/L者延长间隔1周,其中10例(67%)实测谷浓度仍>100 mg/L,未见疾病生物学或临床复发。结论认为基于药代动力学监测安全调整依库珠单抗间隔可行。
要点
- 依库珠单抗维持期统一1200 mg每2周,目标谷浓度50-100 mg/L下许多患者存在过度暴露。
- 群体药代动力学模型预测90%(36/40)患者可延长给药间隔1周。
- 15例延长间隔1周后67%(10例)实测谷浓度仍>100 mg/L,未见疾病复发。
核心结论
- 基于药代动力学监测安全调整依库珠单抗给药间隔是可行的。
研究设计与样本
- 两阶段前瞻性多中心研究,第一阶段用40例患者数据建立群体药代动力学模型。
- 第二阶段对预测谷浓度>100 mg/L的15例患者延长给药间隔1周并监测谷浓度。
主要发现
- 模型证实体重影响消除清除率,预测36例(90%)患者符合延长间隔条件。
- 延长间隔1周后,10例(67%)实测谷浓度>100 mg/L。
- 即使5例谷浓度<100 mg/L并恢复原方案者,也未见疾病生物学或临床复发。
关键数值与推荐
- 依库珠单抗维持期统一剂量为1200 mg每2周。
- 目标谷浓度范围为50-100 mg/L。
- 延长间隔后实测谷浓度>100 mg/L者占67%(10/15)。
临床怎么用
- 可依据药代动力学监测结果,对预测谷浓度>100 mg/L的患者考虑延长给药间隔1周。
- 延长间隔后应监测谷浓度,必要时恢复原方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Eculizumab is an anti-C5 monoclonal antibody approved for rare diseases including atypical haemolytic-uraemic syndrome. The maintenance phase dosing regimen is identical for all adult patients: 1200 mg every 2 weeks. Recent studies reported an overexposure in many patients when considering a target trough concentration range of 50-100 mg/L. The aim of the present work was to validate the feasibility of therapeutic drug monitoring of eculizumab in atypical haemolytic-uraemic syndrome patients. METHODS: We performed a 2-step prospective multicentre study. In the first phase, we developed a pharmacokinetic population model using data from 40 patients and identified patients for whom a 1-week lengthening of interval between infusions would lead to a trough concentration above 100 mg/L. In the second phase, selected patients were allocated a 1-week extension and eculizumab trough concentrations were monitored. RESULTS: The model confirmed the previously reported influence of bodyweight on elimination clearance and predicted that 36 (90%) patients would be eligible for interval extension. In the second phase of the study, a 1-week lengthening of interval between infusions was performed in 15 patients whose trough concentration at the next visit was predicted with a Bayesian model to be above 100 mg/L. After interval extension, 10 patients (67%) presented measured trough concentrations over 100 mg/L. No biological or clinical recurrence of disease was observed, even in the 5 patients with concentrations below 100 mg/L in whom the initial dosing regimen was resumed. CONCLUSION: Safe eculizumab interval adjustment is feasible with a PK monitoring.
引用
- Passot C, Sberro-Soussan R, Bertrand D, et al. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. Br J Clin Pharmacol. 2020. PMID: 33118186. doi:10.1111/bcp.14627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。